These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28493986)

  • 21. Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score.
    Peters AC; Duan Q; Russell JA; Duggan P; Owen C; Stewart DA
    Leuk Lymphoma; 2011 Nov; 52(11):2124-9. PubMed ID: 21740097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.
    Alonso-Álvarez S; Magnano L; Alcoceba M; Andrade-Campos M; Espinosa-Lara N; Rodríguez G; Mercadal S; Carro I; Sancho JM; Moreno M; Salar A; García-Pallarols F; Arranz R; Cannata J; Terol MJ; Teruel AI; Rodríguez A; Jiménez-Ubieto A; González de Villambrosia S; Bello JL; López L; Monsalvo S; Novelli S; de Cabo E; Infante MS; Pardal E; García-Álvarez M; Delgado J; González M; Martín A; López-Guillermo A; Caballero MD
    Br J Haematol; 2017 Sep; 178(5):699-708. PubMed ID: 28782811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi.
    Rossi G; Marcheselli L; Dondi A; Bottelli C; Tucci A; Luminari S; Arcaini L; Merli M; Pulsoni A; Boccomini C; Puccini B; Micheletti M; Martinelli G; Rossi A; Zilioli VR; Bozzoli V; Balzarotti M; Bolis S; Cabras MG; Federico M
    Am J Hematol; 2015 Jan; 90(1):56-61. PubMed ID: 25327841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial.
    Bruna R; Benedetti F; Boccomini C; Patti C; Barbui AM; Pulsoni A; Musso M; Liberati AM; Gini G; Castellino C; Rossini F; Ciceri F; Rota-Scalabrini D; Stelitano C; Di Raimondo F; Tucci A; Devizzi L; Zoli V; Zallio F; Narni F; Dondi A; Parvis G; Semenzato G; Lanza F; Perrone T; Angrilli F; Billio A; Gueli A; Mantoan B; Rambaldi A; Gianni AM; Corradini P; Passera R; Ladetto M; Tarella C
    Haematologica; 2019 Nov; 104(11):2241-2248. PubMed ID: 31666344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial.
    Watanabe T; Tobinai K; Wakabayashi M; Morishima Y; Kobayashi H; Kinoshita T; Suzuki T; Yamaguchi M; Ando K; Ogura M; Taniwaki M; Uike N; Yoshino T; Nawano S; Terauchi T; Hotta T; Nagai H; Tsukasaki K;
    Lancet Haematol; 2018 Nov; 5(11):e520-e531. PubMed ID: 30389034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Life expectancy of young adults with follicular lymphoma.
    Conconi A; Lobetti-Bodoni C; Montoto S; Lopez-Guillermo A; Coutinho R; Matthews J; Franceschetti S; Bertoni F; Moccia A; Rancoita PM; Gribben J; Cavalli F; Gaidano G; Lister TA; Montserrat E; Ghielmini M; Zucca E
    Ann Oncol; 2015 Nov; 26(11):2317-22. PubMed ID: 26362567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study.
    Martinelli G; Montoro J; Vanazzi A; Andreola G; Liptrott S; Radice D; Negri M; Preda L; Pruneri G; Laszlo D
    Hematol Oncol; 2015 Dec; 33(4):129-35. PubMed ID: 25047267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absolute B cell counts in blood predict long-term response in follicular lymphoma patients treated with rituximab without chemotherapy.
    Junlén HR; Lockmer S; Kimby E; Wahlin BE
    Ann Hematol; 2020 Oct; 99(10):2357-2366. PubMed ID: 32808106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure.
    Jiménez-Ubieto A; Grande C; Caballero D; Yáñez L; Novelli S; Hernández-Garcia MT; Manzanares M; Arranz R; Ferreiro JJ; Bobillo S; Mercadal S; Galeo A; López Jiménez J; Moraleda JM; Vallejo C; Albo C; Pérez E; Marrero C; Magnano L; Palomera L; Jarque I; Martínez-Sánchez P; Martín A; Coria E; López-Guillermo A; Salar A; Lahuerta JJ
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1631-1640. PubMed ID: 28533060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: report from the National LymphoCare Study.
    Nabhan C; Byrtek M; Taylor MD; Friedberg JW; Cerhan JR; Hainsworth JD; Miller TP; Hirata J; Link BK; Flowers CR
    Cancer; 2012 Oct; 118(19):4842-50. PubMed ID: 22434428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prognostic Significance of Follicular Lymphoma International Prognostic Index 2 (FLIPI2) in Follicular Lymphoma Patients Treated with Rituximab Maintenance].
    Xu PP; Qian Y; Chen QS; Li LQ; Zhang L; Zhao WL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):426-430. PubMed ID: 28446287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in assessing prognosis and predicting first-line treatment efficacy in follicular lymphoma patients.
    Formica V; Norman AR; Cunningham D; Wotherspoon A; Oates J; Chong G
    Acta Haematol; 2009; 122(4):193-9. PubMed ID: 19887775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.
    Vidal L; Gafter-Gvili A; Salles G; Bousseta S; Oberman B; Rubin C; van Oers MH; Fortpied C; Ghielmini M; Pettengell R; Witzens-Harig M; Dreger P; Vitolo U; Gomes da Silva M; Evangelista A; Li H; Freedman L; Habermann TM; Shpilberg O
    Eur J Cancer; 2017 May; 76():216-225. PubMed ID: 28336303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
    Nicolas-Virelizier E; Ségura-Ferlay C; Ghesquières H; Chassagne-Clément C; Gargi T; Biron P; Belhabri A; Rey P; Faurie P; Chabaud S; Sebban C
    Hematol Oncol; 2015 Mar; 33(1):1-8. PubMed ID: 24496668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy.
    Lockmer S; Ren W; Brodtkorb M; Østenstad B; Wahlin BE; Pan-Hammarström Q; Kimby E
    Br J Haematol; 2020 Jan; 188(2):259-267. PubMed ID: 31423576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients.
    Plancarte F; López-Guillermo A; Arenillas L; Montoto S; Giné E; Muntañola A; Ferrer A; Villamor N; Bosch F; Colomo L; Balaguer O; Campo E; Montserrat E
    Eur J Haematol; 2006 Jan; 76(1):58-63. PubMed ID: 16343272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New treatment options have changed the survival of patients with follicular lymphoma.
    Fisher RI; LeBlanc M; Press OW; Maloney DG; Unger JM; Miller TP
    J Clin Oncol; 2005 Nov; 23(33):8447-52. PubMed ID: 16230674
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
    Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
    Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era.
    Procházka V; Papajík T; Faber E; Raida L; Kapitáňová Z; Langová K; Prouzová Z; Jarošová M; Indrák K
    Leuk Lymphoma; 2014 Jul; 55(7):1584-90. PubMed ID: 24180329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study.
    Federico M; Guglielmi C; Luminari S; Mammi C; Marcheselli L; Gianelli U; Maiorana A; Merli F; Bellei M; Pozzi S; Stelitano C; Lazzaro A; Gobbi PG; Baldini L; Bergantini S; Fregoni V; Brugiatelli M
    Haematologica; 2007 Nov; 92(11):1482-8. PubMed ID: 18024396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.